HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation⢠(nanosecond PFA or nsPFAâ˘) technology, today announced business updates and financial results for the second quarter ended June 30, 2025. Recent Business Highlights Soft Tissue Ablation Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation. Treated over 140 Benign Thyroid Nodule patients to date across multi
Related Questions
How did Pulse Biosciences' Q2 2025 revenue and earnings compare to consensus analyst estimates?
What guidance did the company provide for fullâyear 2025 revenue and earnings per share?
What is the expected timeline for FDA clearance or regulatory approval for the nsPFA Percutaneous Electrode for softâtissue ablation?
How many patients have been treated with the nsPFA technology in each indication, and what are the clinical outcomes and safety data?
What is the revenue contribution of the thyroidânodule program versus other product lines, and how is that revenue recognized (e.g., product sales, collaborations, grant funding)?
What are the projected market sizes for benign thyroid nodule ablation and other softâtissue ablation indications, and how much market share does Pulse aim to capture?
What is the competitive landscape for nanosecond pulsed field ablationâwho are the main competitors and how does Pulse's technology differentiate in efficacy, safety, and cost?
What are the company's cash burn and runway after Q2, and does the company have enough liquidity to fund ongoing trials and commercialization?
Did the company announce any new partnership, licensing, or coâdevelopment agreements in Q2, and what are the terms (upâfront, milestones, royalties)?
What is the status of the pilot program â is it expanding to additional sites or indications, and what are the enrollment targets and timelines for a pivotal trial?
What risk factors were highlighted in the earnings release (e.g., regulatory risk, technology adoption risk, reimbursement uncertainty) that could affect the valuation?
How will the expanded pilot program affect shortâterm operating expenses and gross margin assumptions?
What is the anticipated impact on the share price in the near term, given the sentiment score of 60 and the market's reaction to previous earnings releases?
Are there any upcoming catalyst events (e.g., data readouts, regulatory submissions, investor presentations) that could drive volatility in PLSE stock?